{
    "id": 26019,
    "fullName": "JAK1 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "JAK1 inact mut indicates that this variant results in a loss of function of the Jak1 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3716,
        "geneSymbol": "JAK1",
        "terms": [
            "JAK1",
            "JAK1A",
            "JAK1B",
            "JTK3"
        ]
    },
    "variant": "inact mut",
    "createDate": "02/09/2017",
    "updateDate": "10/08/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21277,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, T-cell acute lymphoblastic leukemia cells harboring a JAK1 nonsense mutation and TYK2 E957D demonstrated resistance to Xeljanz (tofacitinib) in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 36165,
                "profileName": "JAK1 inact mut TYK2 E957D"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21275,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tyrphostin B42 (AG-490) inhibited proliferation of T-cell acute lymphoblastic leukemia cells harboring a JAK1 nonsense mutation and TYK2 E957D in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 36165,
                "profileName": "JAK1 inact mut TYK2 E957D"
            },
            "therapy": {
                "id": 2783,
                "therapyName": "Tyrphostin B42",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21276,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pyridone 6 (CMP6) inhibited proliferation of T-cell acute lymphoblastic leukemia cells harboring a JAK1 nonsense mutation and TYK2 E957D in culture (PMID: 23471820).",
            "molecularProfile": {
                "id": 36165,
                "profileName": "JAK1 inact mut TYK2 E957D"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 5603,
                "name": "T-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17688,
                    "pubMedId": 23471820,
                    "title": "TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23471820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27159,
            "profileName": "JAK1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 36165,
            "profileName": "JAK1 inact mut TYK2 E957D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}